

Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/105863/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Khan, Raysa, Boonseng, Sarote, Kemmitt, Paul D., Felix, Robert, Coles, Simon J., Tizzard, Graham J., Williams, Gareth, Simmonds, Olivia, Harvey, Jessica-Lily, Atack, John ORCID: <https://orcid.org/0000-0002-3410-791X>, Cox, Hazel and Spencer, John 2017. Combining Sanford Arylations on Benzodiazepines with the nuisance effect. *Advanced Synthesis & Catalysis* 359 (18) , pp. 3261-3269. 10.1002/adsc.201700626 file

Publishers page: <http://dx.doi.org/10.1002/adsc.201700626>
<<http://dx.doi.org/10.1002/adsc.201700626>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies.

See

<http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Combining Sanford Arylations on Benzodiazepines with the Nuisance Effect

Raysa Khan,^a Sarote Boonseng,^a Paul D. Kemmitt,^b Robert Felix,^c Simon J. Coles,^d Graham J. Tizzard,^d Gareth Williams,^e Olivia Simmonds,^e Jessica-Lily Harvey,^e John Attack,^e Hazel Cox,^a and John Spencer^{a,*}

^a Department of Chemistry, School of Life Sciences, University of Sussex, Falmer, BN1 9QJ, UK
E-mail: h.cox@sussex.ac.uk; j.spencer@sussex.ac.uk

^b Oncology, AstraZeneca, 310 Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, UK

^c Tocris Bioscience, the Watkins Building, Atlantic Road, Avonmouth, Bristol, BS11 9QD, UK

^d UK National Crystallography Service, School of Chemistry, University of Southampton, Highfield, Southampton, SO17 1BJ, U.K.

^e Sussex Drug Discovery Centre, School of Life Sciences, University of Sussex, Falmer, BN1 9QJ, UK

Received: May 17, 2017; Revised: June 29, 2017; Published online: August 2, 2017



Supporting information for this article is available on the WWW under <https://doi.org/10.1002/adsc.201700626>

© 2017 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Abstract: 5-Phenyl-1,3-dihydro-2*H*-1,4-benzodiazepin-2-ones react under palladium- and visible light photoredox catalysis, in refluxing methanol, with aryldiazonium salts to afford the respective 5-(2-arylphenyl) analogues. With 2- or 4-fluorobenzenediazonium derivatives, both fluoroaryl- and methoxyaryl- products were obtained, the latter resulting from a S_NAr on the fluorobenzenediazonium salt (“nuisance effect”). A computational DFT analysis of the palladium-catalysed and the palladium/ruthenium-photocatalysed mechanism for the functionalization of benzodiazepines indicated that, in the presence of the photocatalyst, the reaction proceeds via a low-energy SET pathway avoiding the high-energy oxidative addition step in the palladium-only catalysed reaction pathway.

Keywords: C–H activation; benzodiazepine; photocatalysis; palladacycle; DFT

1 Introduction


There is a growing impetus for atom economical routes to high value end products employing late stage functionalization (LSF) processes.^[1] These are particularly desirable in medicinal chemistry since they increase diversity and chemical space and enable rapid

SAR (structure activity relationship) and ADME-Tox (Absorption, distribution, metabolism, elimination-toxicity) feedback that is key to costly, high attrition, drug development. Late stage C–H activation is a powerful tool in generating novel compounds for biological evaluation.^[2] We recently described a palladium-catalyzed ortho-arylation of benzodiazepines employing iodonium salts in acetic acid under microwave irradiation.^[3] The harsh conditions, relatively high commercial cost, and multistep synthesis of iodonium salts^[4] ($ArIAr'^{+}$), coupled with a poor atom economy ($Ar-I$ is a byproduct) prompted us to consider a visible-light photocatalyzed Pd-mediated protocol involving diazonium salts.^[5]

2 Results and Discussion

Our initial reaction trials were performed on the benzodiazepine **1a**, using the 2-fluoro-benzenediazonium salt **2a** under reflux (external oil bath temperature set at 70 °C). To our surprise, in addition to the expected product **3a**, we were able to isolate the ether product **4a**. However, reaction of the 3-isomer **2b** led exclusively to the fluoroaryl derivative **3b**, whereas the 4-isomer **2c** afforded a mixture of fluoroaryl **3c** and methoxy product **4c** (Scheme 1). Repeating the reaction in ethanol led to the ethyl ether **4d** whose x-ray structure is displayed (Scheme 1).

Characterization of **4c** was enabled by determination of its solid state x-ray structure^[6] (Scheme 1) and



Scheme 1. Benzodiazepine library synthesis.

by its unequivocal synthesis starting from 4-methoxybenzenediazonium tetrafluoroborate **2d** (Table 1) where we found slightly better yields under reflux (Entry 1 vs. 2) compared to either ambient temperature or to the absence of photocatalyst (Entry 5). Moreover, a palladium catalyst was essential (Entry 4) for achieving a good yield. Microwave-mediated chemistry, in the absence of light and photocatalyst, gave little conversion of product.

To explain the formation of the ether products we propose a competing S_NAr , termed “nuisance effect,”


Table 1. Synthesis of an anisole derivative.

Entry	Lamps 26 W	Pd(OAc) ₂ (mol%)	Ru(bpy) ₃ Cl ₂ · 6H ₂ O (mol%)	Temp. (°C)	Conv. LC/MS (%)
1	Yes	10	2.5	rt	52
2	Yes	10	2.5	Reflux ^[a]	61
3	No	10	2.5	Reflux ^[a]	35
4	Yes	0	2.5	Reflux ^[a]	0
5	Yes	10	0	Reflux ^[a]	57
6	No	10	0	[b]	20

^[a] External oil bath temperature; 70 °C,


^[b] microwave (MW), 125 °C, 1 h.

which has historically been observed for halogen-substituted benzenediazonium salts, given the strong electron withdrawing effects of the diazo group, notably operating on the 2- and 4-substituted isomers.^[7] Indeed, simple alcoholysis of compound **2c** was achieved in the appropriate alcohol solvent at 70 °C (Scheme 2).



Scheme 2. “Nuisance effect” on diazonium salts.

The C–H activation reaction was also applied to aryldiazoniums incapable of undergoing such a F-substitution and, hence derivatives **4e–4i** were synthesized in good to excellent yields (Scheme 3) and the structure of **4h** was determined by x-ray crystallography. Indeed, yields tend to be either similar or higher than those reported for the corresponding reactions involving iodonium salts, e.g. **4e** (60% vs. 56%), **4f** (54% vs. 35%), **4g** (71% vs. 55%) and **4i** (64% vs. 63%).



Scheme 3. Other arylated benzodiazepines.

In the synthesis of **4i**, relatively large amounts of the diarylated adduct **4i'** were also observed. Such diarylations were previously reported by us.^[3b]

The current and previous library of benzodiazepines (Scheme 1) was tested for GABA binding.^[8]


None of the current benzodiazepines displayed any appreciable biological activity although 7-chloro-benzodiazepines, as expected, had reasonable activity, although were *ca.* 7–10 fold less active than nordazepam and diazepam controls (Entries 1 and 2 respectively, Table 2) and were not pursued any further.

Table 2. GABA activity of library.

Entry	Compound	mean K_i (nM)/ SEM (nM) vs. GABA.
1		51.62 ± 2.0
2		41.41 ± 4.9
3		373.45 ± 110.5
4		421.54 ± 86.1
5		303.25 ± 60.7
6		689.56 ± 480.3

Sanford et al. proposed a possible mechanism to explain their Pd/Ru photocatalysed C–H arylation.^[5a] Here we present a computational study of a Pd-catalysed and a Sanford-derived Pd/Ru photocatalysed mechanism for the functionalization of **1a** to **4g** (Scheme 4) to rationalise the increased yield in the presence of light and a Ru photocatalyst.

The detailed mechanism is shown in Scheme 5 and the reaction profile (relative to the reactants) in Figure 1. The reaction mechanism, with and without the Ru(II)-photocatalyst, essentially follows the same path except that the oxidative addition step in the presence of just the Pd(II)-catalyst (path shown in




Scheme 4. The formation reaction of **4g** with (i) and without (ii) the Ru photocatalyst, investigated using DFT.

green, Scheme 5 and Figure 1), is replaced by a single-electron-transfer (SET) process when the Ru(II)-photocatalyst is added (shown in red, Scheme 5 and Figure 1).

The initial step of the catalysed mechanism involves the coordination to Pd(OAc)₂ by a N atom on the un-functionalised benzodiazepine to provide **Int1**, followed by the formation of an agostic complex **Int2** prior to C–H activation. The atomic distance between Pd and the agostic H in **Int2** is 1.903 Å, which is in good agreement with similar agostic interactions in the literature: Pd–H = 1.91 Å^[9] and Rh–H (1.95 Å).^[10] The barrier to C–H bond activation is 41.4 kJ mol^{−1}, and involves H migration from C to O via a six-membered ring (**TS2-3**). Prior to coordination with the *p*-nitrobenzenediazonium (Ar–N₂⁺) the complex undergoes an isomerisation step (**TS3-4**), which involves a change in the C1–Pd–O3 angle from 132.0 to 172.0 degrees with an energy barrier of 27.8 kJ mol^{−1} to form **Int4**.

In the absence of the photocatalyst, Ar–N₂⁺ interacts with the Pd(II) complex and follows an oxidative addition (OA) pathway, (highlighted in green, Scheme 5 and Figure 1). The oxidative addition via **TS5-6(OA)** has an energy barrier of 127.1 kJ mol^{−1} and involves the formation of an Ar–Pd(IV) complex. The N₂ is then eliminated leading to **Int7**.

When the Ru(II)-photocatalyst is present, the nitrobenzene radical (Ar*) is generated from Ar–N₂⁺ (via oxidative quenching of Ar–N₂⁺ by the photo-excited [Ru(bpy)₃]²⁺ complex to form [Ru(bpy)₃]³⁺)^[11] and follows a single-electron-transfer (SET) pathway, (in red, Scheme 5 and Figure 1). The square planar geometry of the Pd(II) complex **Int4** becomes a Pd(III) distorted-octahedral structure when the Ar binds to the Pd centre in **Int5(SET)**; this is consistent with the crystal structure of other Pd(III)-complexes although we did not consider bimetallic species.^[12] **Int7** is formed directly from **Int5(SET)** by the transfer of an electron to the [Ru(bpy)₃]³⁺ complex to recover



Scheme 5. The reaction mechanism for the functionalization of benzodiazepine. From **Int4** to **Int7** the transformation follows the green path in the presence of the Pd catalyst and the red path in the presence of the Pd/Ru catalysts. Both paths were considered.

the photocatalyst. The Gibbs free energy barrier for single electron transfer (SET) resulting in the formation of the Pd(IV) complex **Int7** was calculated to be 2.5 kJ mol⁻¹ using Marcus and Savéant theory.^[13] The details of this calculation are provided in the Computational Method section. This barrier is very small but similar to literature values that range from 0.4–15.1 kJ mol⁻¹.^[14]

Both mechanisms (OA and SET) result in the same Pd(IV) structure for **Int7**. At this stage reductive elimination occurs via **TS7-8** with a barrier of

43.2 kJ mol⁻¹. This step involves the formation of a C–C bond to facilitate the functionalization of the benzodiazepine and the oxidation state of the Pd-center changes from Pd(IV) to Pd(II) (**Int7**→**Int8**). The geometry **Int8**, involves an $\eta^2(\text{C}=\text{C})$ interaction with Pd. A similar interaction was observed by Ariafard et al.^[15] and Canty et al.^[16] in their DFT calculations and in a palladium complex crystal structure.^[17]

It is clear from Figure 1 that, in the presence of the Pd-catalyst, the oxidative addition step is rate determining with a considerable energy barrier. However, in the presence of both the Pd(II)-catalyst and the Ru(II)-photocatalyst this OA step, and hence large energy barrier, is avoided as the reaction proceeds via a very low-energy single-electron-transfer process. This provides a rationale for the increased yield in the presence of a photocatalyst.

Conclusion

The C–H activation of benzodiazepines with 2- or 4-fluorobenzene diazonium salts under Pd catalysis with a Ru photocatalyst, in alcohol solvent, under reflux, leads to a mixture of both fluoroaryl and alkoxyaryl products. Reaction temperature is a key factor in determining the ratio of expected vs. “nuisance effect” ($\text{S}_{\text{N}}\text{Ar}$) products. At ambient temperature trace amounts of the $\text{S}_{\text{N}}\text{Ar}$ product are detected whereas significant amounts can be obtained after prolonged heating under reflux. This process can also be extended to other aryl diazonium salts affording ortho-arylated benzodiazepines. These were tested for biological activity but were found to be significantly less active than e.g. nordazepam and diazepam controls. Density functional theory (DFT) has been used to provide a detailed mechanistic understanding of the functionalization of the benzodiazepines and to offer an explanation for the increased yield in the presence of a Ru(II)-photocatalyst. The Pd/Ru catalytic cycle follows the mechanism proposed by Sandford et al.^[5a] The increased yield in the visible-light photocatalysed Pd-mediated protocol is attributed to the transformation step leading to the formation of the Pd(IV) complex. In the presence of the photocatalyst the reaction proceeds via a low-energy SET pathway and avoids the high-energy oxidative addition step in the Pd-only catalysed reaction pathway.

Current studies are aiming to extend the arylation/nuisance effect chemistry to a wider scope of privileged structures with different nucleophiles for application in medicinal chemistry library generation and will be reported in due course.




Figure 1. The reaction energy profile for the formation of **4g** from **1a**, with (red path) and without (green path) a photocatalyst. Steps common to both mechanisms are shown in blue. $[\text{Ru}^{2+}]$ and $[\text{Ru}^{3+}]$ represent $[\text{Ru}(\text{bpy})_3]^{2+}$ and $[\text{Ru}(\text{bpy})_3]^{3+}$, respectively.

Experimental Section

General Information

All reactions were conducted under an inert atmosphere unless specified otherwise. All commercially purchased materials and solvents were used without further purification unless specified otherwise.

NMR spectra were recorded on a Varian V NMRS 500 (^1H : 500 MHz, ^{13}C : 126 MHz) spectrometer and prepared in deuterated solvents such as CDCl_3 and $\text{DMSO}-d_6$. ^1H and ^{13}C chemical shifts were recorded in parts per million (ppm). Multiplicity of ^1H -NMR peaks are indicated by s – singlet, d – doublet, dd – doublets of doublets, t – triplet, pt – pseudo triplet, q – quartet, m – multiplet and coupling constants are given in Hertz (Hz).

Electrospray ionisation – high resolution mass spectra (ESI-HRMS) were obtained using a Bruker Daltonics Apex III where Apollo ESI was used as the ESI source. All analyses were conducted by Dr A. K. Abdul-Sada at Sussex. The molecular ion peaks $[\text{M}]^+$ were recorded as mass to charge (m/z) ratio.

LC–MS spectra were acquired using a Shimadzu LC–MS 2020, on a Gemini 5 μm C18 110 Å column and percentage purities were run over 30 minutes in water/acetonitrile with 0.1% formic acid (5 min at 5%, 5%–95% over 20 min, 5 min at 95%) with the UV detector at 254 nm. Purifications were performed by flash chromatography on silica gel columns or C18 columns using a Combi flash RF 75 PSI, ISCO unit. The following CCDC deposition numbers have been obtained, in parentheses; for **4c** (1518056), **4d** (1551609) and **4h** (1551610).

4-Methoxybenzenediazonium Tetrafluoroborate (**2d**)

A stirred suspension of 4-fluorobenzenediazonium tetrafluoroborate (0.10 g, 0.48 mmol) in methanol (2 mL) was heated at 70 °C by using an external oil bath for 1 hour. The reaction was allowed to cool to ambient temperature and concentrated under reduced pressure. The residue was precipitated by the addition of diethyl ether and collected by filtration, affording **2d** as a white solid (0.090 g, 85%). The spectral data were concurrent with those reported.^[18]

4-Ethoxybenzenediazonium Tetrafluoroborate (**2e**)

The reaction was conducted by the same procedure as for **2d** but ethanol (2 mL) was used instead of methanol and heated at 70 °C for 1 hour. **2e** was obtained as a white solid (0.071 g, 63%). The spectral data were concurrent with those reported.^[19]

2-Methoxybenzenediazonium Tetrafluoroborate (**2f**)

The reaction was conducted by the same procedure as for **2d** but 2-fluorobenzenediazonium tetrafluoroborate (0.10, 0.48 mmol) was used instead. **2f** was obtained as a white solid (0.073 g, 72%). The spectral data were concurrent with those reported.

5-(2'-Fluorobiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (3a);

5-(2'-methoxybiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (4a)

5-Phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one (0.070 g, 0.3 mmol), 2-fluorobenzenediazonium tetrafluoroborate (0.25 g, 1.20 mmol) and palladium (II) acetate (0.0067 g, 0.03 mmol) were suspended in degassed, anhydrous methanol (5 mL). Two fluorescent light bulbs (26 W) were placed on either side of the reaction vessel and the reaction mixture was heated at 70 °C by using an external oil bath for 4 hours. The reaction was allowed to cool to ambient temperature, diluted with ethyl acetate (50 mL), washed with water (20 mL) and aqueous sodium sulphite (10%, 35 mL × 2). The layers were separated and the combined aqueous layers were extracted with ethyl acetate (50 mL). Thereafter the combined organic layer was washed with brine (50 mL), dried (MgSO₄) and concentrated under reduced pressure. The resulting crude material was purified by reversed phase chromatography (water/acetonitrile with 0.1% formic acid, 5 min at 0%, 30%–90%). Starting material **1a** was recovered (0.014 g, 0.06 mmol). Two products were generated; **3a** was obtained as a white solid (0.022 g, 28%) and **4a** was obtained as a white solid (0.030 g, 37%). **3a**: The spectral data were concurrent with those reported.³ **4a**: ¹H-NMR (500 MHz) CDCl₃: δ = 7.98 (s, NH, 1H), 7.68 (d, ³J_{HH} = 7.0 Hz, ArH, 1H), 7.52–7.42 (m, ArH, 2H), 7.28 (d, ³J_{HH} = 8.0 Hz, ArH, 1H), 7.19–7.12 (m, ArH, 1H), 7.06–6.98 (m, ArH, 2H), 6.90–6.83 (m, ArH, 1H), 6.80 (d, ³J_{HH} = 7.5 Hz, ArH, 1H), 6.69–6.60 (m, ArH, 2H), 6.52 (d, ³J_{HH} = 8.0 Hz, ArH, 1H), 4.22 (s, COCH₂, 2H), 3.51 (s, O-CH₃, 3H). ¹³C-NMR (126 MHz) CDCl₃: δ = 173.1 (C=O), 171.1 (C=N), 156.1 (ArC), 140.8 (ArC), 139.0 (ArC), 137.4 (ArC), 131.3 (ArC), 131.5 (ArC), 131.4 (ArC), 131.1 (ArC), 130.3 (ArC), 129.8 (ArC), 129.6 (ArC), 129.3 (ArC), 128.9 (ArC), 127.7 (ArC), 123.3 (ArC), 120.3 (ArC), 120.2 (ArC), 110.0 (ArC), 56.7 (COCH₂), 55.3 (O-CH₃). HRMS-ESI (m/z) calculated for C₂₂H₁₈FN₂O₂ [+H]⁺: 343.1441, found: 343.1446. LCMS purity (UV) = 96%, tR 10.63 min.

5-(3'-Fluorobiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (3b)

The reaction was conducted on a 0.20 mmol scale by the same procedure as for **3a/4a** but 3-fluorobenzenediazonium tetrafluoroborate (0.17 g, 0.8 mmol) was used instead of 2-fluorobenzenediazonium tetrafluoroborate. Starting material, **1a** was recovered (0.010 g, 0.042 mmol) and **3b** was obtained as a white solid (0.040 g, 77%). The spectral data were concurrent with those reported.

5-(4'-Fluorobiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (3c);

5-(4'-Methoxybiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (4c)

This reaction was conducted on a 0.42 mmol scale by the same procedure as **3a/4a** and 4-fluorobenzenediazonium tetrafluoroborate (0.35 g, 1.67 mmol) was used instead of 2-

fluorobenzenediazonium tetrafluoroborate. Starting material, **1a** was recovered (0.015 g, 0.06 mmol) and the reaction generated two products; **3c** was obtained as a white solid (0.053 g, 45%) and **4c** was obtained as a white solid (0.038 g, 32%). **3c**: ¹H-NMR (500 MHz) DMSO-d₆: δ = 10.39 (s, ArH, 1H), 7.60–7.55 (m, 1H), 7.55–7.52 (m, ArH, 1H), 7.50 (d, ³J_{HH} = 7.5 Hz, ArH, 1H), 7.33–7.30 (m, ArH, 1H), 7.21–7.17 (m, ArH, 1H), 6.92–6.86 (m, ArH, 4H), 6.83–6.77 (m, ArH, 2H), 6.69 (d, ³J_{HH} = 8.0 Hz, 1H), 4.03 (s, COCH₂, 2H).

¹³C-NMR (126 MHz) DMSO-D₆: δ = 172.1 (C=O), 169.7 (C=N), 161.5 (d, ¹J_{FC} = 244.0 Hz, ArC), 140.4 (ArC), 139.8 (ArC), 139.2 (ArC), 136.9 (ArC), 131.5 (ArC), 130.4 (ArC), 130.5 (d, ³J_{FC} = 7.5 Hz, 2 × ArC), 130.2 (ArC), 130.1 (ArC), 129.3 (ArC), 128.3 (ArC), 127.8 (ArC), 122.7 (ArC), 120.7 (ArC), 114.9 (d, ²J_{FC} = 22.0 Hz, 2 × ArC), 57.3 (COCH₂). HRMS-ESI (m/z) calculated for C₂₁H₁₅FN₂O [+H]⁺: 331.1241, found: 331.1244. LCMS purity (UV) = 92%, tR 11.16 min. **4c**: The spectral data were concurrent with those reported.

5-(4'-Ethoxybiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (4d)

The same method as that of **3a/4a** was used but ethanol (5 mL) was used as the solvent instead of methanol. Starting material, **1a**, was recovered (0.020 g, 0.085 mmol). Two products were generated, product **3c** was obtained as a white solid (0.043 g, 39%) and Product **4d** was obtained as a white solid (0.026 g, 22%). **4d**: ¹H-NMR (500 MHz) CDCl₃: δ = 8.20 (s, NH, 1H), 7.68 (d, ³J_{HH} = 7.5 Hz, ArH, 1H), 7.57–7.38 (m, ArH, 2H), 7.28 (d, ³J_{HH} = 7.5 Hz, ArH, 1H), 7.15 (pt, ³J_{HH} = 7.5 Hz, ArH, 1H), 6.91–6.81 (m, ArH, 4H), 6.69 (d, ³J_{HH} = 8.0 Hz, ArH, 1H), 6.60 (d, ³J_{HH} = 8.0 Hz, ArH, 2H), 4.29 (s, COCH₂, 2H), 3.94 (q, ³J_{HH} = 7.0 Hz, O-CH₂CH₃, 2H), 1.36 (t, ³J_{HH} = 7.0 Hz, O-CH₂CH₃, 3H). ¹³C-NMR (126 MHz) CDCl₃: δ = 173.2 (C=O), 170.7 (C=N), 157.8 (ArC), 141.7 (ArC), 139.5 (ArC), 137.3 (ArC), 133.2 (ArC), 131.1 (ArC), 130.1 (ArC), 129.9 (ArC), 129.7 (ArC), 129.8 (2 × ArC), 129.5 (ArC), 129.1 (ArC), 128.1 (ArC), 126.9 (ArC), 123.1 (ArC), 113.8 (2 × ArC), 63.5 (O-CH₂CH₃), 56.5 (COCH₂), 14.8 (O-CH₂CH₃). HRMS-ESI (m/z) calculated for C₂₃H₂₀N₂O₂ [+Na]⁺: 379.1417, found: 379.1419. LCMS purity (UV) = 87%, tR 10.89 min.

5-Phenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (4e)

The reaction was conducted by the same procedure as for **3a/4a** but benzenediazonium tetrafluoroborate (0.23 g, 1.20 mmol) was used instead of 2-fluorobenzenediazonium tetrafluoroborate. Starting material **1a** was recovered (0.016 g, 0.067 mmol) and **4e** was obtained as a white solid (0.043 g, 60%). All spectral data were concurrent with those reported.

5-(4'-Methoxybiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (4f)

The reaction was conducted on a 0.32 mmol scale by the same procedure as for **3a/4a** but 4-methoxybenzenediazonium tetrafluoroborate (0.28 g, 1.28 mmol) was used instead of 2-fluorobenzenediazonium tetrafluoroborate. Starting material, **1a** was recovered (0.015 g, 0.063 mmol) and **4f** was obtained as a white solid (0.048 g, 54%). All spectral data were concurrent with those reported.

5-(4'-Nitrobiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (4g)

The reaction was conducted on a 0.45 mmol scale by the same procedure as for **3a/4a** but 4-nitrobenzenediazonium tetrafluoroborate (0.43 g, 1.80 mmol) was used instead. Starting material, **1a** was recovered (0.020 g, 0.085 mmol) and **4g** was obtained as a white solid (0.093 g, 71%). ¹H-NMR (500 MHz) CDCl₃: δ = 8.78 (s, 1H), 7.94 (dd, ³J_{HH} = 8.5, 1.5 Hz, 2H), 7.78–7.72 (m, 1H), 7.60–7.52 (m, 2H), 7.34–7.28 (m, 1H), 7.22–7.13 (m, 3H), 6.90–6.83 (m, 2H), 6.72 (d, ³J_{HH} = 8.0 Hz, 1H), 4.31 (s, COCH₂, 2H). ¹³C-NMR (126 MHz) CDCl₃: δ = 172.1 (C=O), 170.6 (C=N), 147.4 (ArC), 146.6 (ArC), 139.7 (ArC), 139.6 (ArC), 137.5 (ArC), 131.7 (ArC), 130.4 (ArC), 129.9 (ArC), 129.8 (ArC), 129.6 (ArC), 129.5 (ArC × 2), 128.7 (ArC), 128.6 (ArC), 123.3 (ArC), 122.7 (ArC × 2), 120.1 (ArC), 56.5 (COCH₂). HRMS-ESI (m/z) calculated for C₂₁H₁₅N₃O₃ [H]⁺: 358.1186, found: 358.1191. Elemental Analysis: Calculated for C₂₁H₁₅N₃O₃ (%): C, 70.58, H, 4.23, N, 11.76, found: C, 70.41, H, 4.23, N, 11.60.

5-(4'-Bromobiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (4h)

The reaction was conducted on a 0.25 mmol scale by the same procedure as for **3a/4a** but 4-bromobenzenediazonium tetrafluoroborate (0.27 g, 1.0 mmol) was used instead. Starting material, **1a** was recovered (0.012 g, 0.051 mmol) and **4h** was obtained as a white solid (0.051 g, 65%). ¹H-NMR (500 MHz) DMSO-d₆: δ = 10.44 (s, 1H), 7.56 (pt, ³J_{HH} = 8.0 Hz, 2H), 7.54–7.48 (m, 1H), 7.34 (d, ³J_{HH} = 8.0 Hz, 1H), 7.28 (d, ³J_{HH} = 8.0 Hz, 2H), 7.23 (pt, ³J_{HH} = 7.5 Hz, 1H), 6.87 (dd, J = 8.0, 5.9 Hz, 3H), 6.82 (pt, ³J_{HH} = 7.5 Hz, 1H), 6.73 (d, ³J_{HH} = 8.0 Hz, 1H), 4.05 (s, COCH₂, 2H). ¹³C-NMR (126 MHz) DMSO-d₆: δ = 171.9 (C=O), 169.8 (C=N), 140.2 (ArC), 139.8 (ArC), 139.6 (ArC), 139.3 (ArC), 131.5 (ArC), 131.1 (ArC), 131.0 (ArC × 2), 130.6 (ArC × 2), 130.3 (ArC), 130.2 (ArC), 130.1 (ArC), 129.5 (ArC), 128.2 (ArC), 128.1 (ArC), 122.7 (ArC), 120.7 (ArC), 56.7 (COCH₂). HRMS-ESI (m/z) calculated for C₂₁H₁₅BrN₂O [H]⁺: 391.0441, found: 391.0449. LCMS purity (UV) = 95%, tR 14.56 min.

5-(3'-Trifluoromethylbiphenyl-2-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (4i);

5-(3,3'-bistrifluoromethylbiphenyl-2,6-yl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (4i')

The reaction was conducted on a 0.39 mmol scale by the same procedure as for **3a/4a** but 3-trifluoromethylbenzene-

diazonium tetrafluoroborate (0.41 g, 1.56 mmol) was used instead. **4i** was obtained as a brown solid (0.094 g, 64%) and the bisarylated product, **4i'**, was obtained as a brown solid (0.061 g, 30%). **4i**: All spectral data were concurrent with those reported. **4i'**: ¹H-NMR (500 MHz) DMSO-d₆: δ = 10.01 (s, 1H), 7.66 (pt, ³J_{HH} = 7.5 Hz, 1H), 7.55 (d, ³J_{HH} = 8.0 Hz, 2H), 7.50 (d, ³J_{HH} = 7.5 Hz, 2H), 7.45 (pt, ³J_{HH} = 7.5 Hz, 2H), 7.41–7.36 (m, 4H), 7.22–7.18 (m, 1H), 6.96–6.89 (m, 2H), 6.75 (d, J = 8.0 Hz, 1H), 3.65 (s, COCH₂, 2H). ¹³C-NMR (126 MHz) CDCl₃: δ = 170.4 (C=O), 169.6 (C=N), 141.4 (ArC), 141.0 (ArC), 138.1 (ArC), 137.4 (ArC), 132.4 (ArC × 2), 131.7 (ArC), 130.1 (q, ²J_{FC}, 33 Hz, ArC × 2), 129.8 (ArC × 2), 129.4 (ArC × 2), 129.3 (ArC × 2), 128.7 (ArC), 128.2 (ArC × 2), 125.8 (q, ³J_{FC}, 3.5 Hz, ArC × 2), 123.9 (q, ³J_{FC}, 272.0 Hz ArC × 2), 123.7 (q, ³J_{FC}, 3.5 Hz, ArC × 2), 123.4 (ArC), 120.2 (ArC), 55.7 (COCH₂). C₂₉H₁₈F₆NO₂ [H]⁺: 525.1396, found: 525.1402. LCMS purity (UV) = 98%, tR 22.50 min.

3 Computational Details

Density functional theory (DFT) calculations were performed at the ωB97XD/6-311++G(2df,2p)[SDD]/PBE/6-31+G(d,p)[SDD] level of theory, using the Gaussian09 program.^[20] The Pople basis sets were used on all atoms except Pd and Ru for which the SDD relativistic effective core potentials were used.^[21] The PBE functional^[22] was used for the geometry optimisation and frequency analysis as it combines good accuracy for Pd complexes with computational speed.^[23] The long-range corrected hybrid functional ωB97XD,^[24] which includes empirical dispersion corrections, was used for energies to ensure accurate energetics.^[25] Methanol solvent energy corrections were applied using the conductor-like polarisable continuum model (CPCM).^[26] Accordingly, the Gibbs free energies presented in Figure 1 were obtained by adding the thermal free energy corrections obtained at the PBE/6-31+G(d,p)[SDD] level of theory to the solvent-corrected electronic energies obtained at the ωB97XD/6-311++G(2df,2p)[SDD] level of theory. All stationary states were verified as minima or transition states by the absence or presence, respectively, of a single imaginary vibrational frequency. Eigenvector following was used to ensure transition states connected the desired minima.

The Gibbs free energy barrier for single electron transfer (SET), ΔG_{ET}[‡], was calculated using the following equation from Marcus and Savéant theory:^[13b-d]

$$\Delta G_{ET}^{\ddagger} = \Delta G_0^{\ddagger} \left[1 + \frac{\Delta G_r}{4\Delta G_0^{\ddagger}} \right]^2 \quad (1)$$

Here ΔG_r is the reaction energy for the electron transfer step and ΔG₀[‡] is the intrinsic barrier, which can be calculated as:

$$\Delta G_0^\ddagger = \frac{\lambda}{4} \quad (2)$$

In Eq. (2), λ is the reorganisation energy and consists of the inner reorganisation energy of the reactants, λ_i , and the solvent reorganisation energy, λ_o . For outer-sphere electron transfer as in the present case, λ_i is assumed to be zero (following literature precedents^[27]) thus λ is equal to λ_o .

The reaction energy for the electron transfer step ΔG_r is calculated as the energy of the reaction: Pd(III)-complex + [Ru(bpy)₃]³⁺ → Pd(IV)-complex + [Ru(bpy)₃]²⁺ (i.e. **Int5(SET)** to **Int7**, Scheme 5). The energy for this step is −83.4 kJ mol^{−1}.

The reorganisation energy $\lambda = \lambda_o$ is calculated using the following equation:^[27–28]

$$\lambda_o = \frac{N_A e^2}{4\pi\epsilon_0} \left(\frac{1}{\epsilon_{op}} - \frac{1}{\epsilon_s} \right) \left(\frac{1}{2r_1} + \frac{1}{2r_2} - \frac{1}{R} \right) \quad (3)$$

where N_A is the Avogadro constant (6.022 × 10²³ mol^{−1}), e is the electronic charge (1.602 × 10^{−19} C), ϵ_0 is the vacuum permittivity (8.854 × 10^{−12} J^{−1}C²m^{−1}) and, ϵ_{op} and ϵ_s are the optical and static dielectric constant for solvent, respectively. For methanol, ϵ_{op} is 1.76 and ϵ_s is 32.613. r_1 , r_2 and R are the hard sphere radii of the donor, the acceptor, and their sum. In this work, the hard sphere radii approximation of [Ru(bpy)₃]³⁺ and the Pd(III)-complex (**Int5(SET)**) were calculated using the VOLUME keyword in Gaussian09. The calculated [Ru(bpy)₃]³⁺ radius is 6.18 Å and the calculated Pd(III)-complex radius is 6.47 Å. Using these values in Eq. (3) gives $\lambda_o = 59.1$ kJ mol^{−1}, and hence $\Delta G_0^\ddagger = 14.8$ kJ mol^{−1}. Substituting these values for ΔG_0^\ddagger and ΔG_r in Eq. (1), provides a SET barrier, $\Delta G_{ET}^\ddagger = 2.5$ kJ mol^{−1}.

Acknowledgements

EPSRC, AstraZeneca and Tocris are thanked for financial support (grant # EP/M507568/1). We would also like to thank the Royal Thai Government for the fully funded PhD scholarship awarded to SB and we acknowledge the use of the EPSRC UK National Service for Computational Chemistry Software (NSCCS) at Imperial College London in performing part of this work. We also thank the EPSRC UK National Mass Spectrometry Facility at Swansea University.

References

- [1] T. Cernak, K. D. Dykstra, S. Tyagarajan, P. Vachal, S. W. Krska, *Chem. Soc. Rev.* **2016**, 45, 546–576.
- [2] a) M. A. J. Duncton, *MedChemComm* **2011**, 2, 1135; b) T. Gensch, M. N. Hopkinson, F. Glorius, J. Wencel-Delord, *Chem. Soc. Rev.* **2016**, 45, 2900–2936; c) T. A.

- Bedell, G. A. Hone, D. Valette, J. Q. Yu, H. M. Davies, E. J. Sorensen, *Angew. Chem. Int. Ed. Engl.* **2016**, 55, 8270–8274; d) A. Sharma, J. F. Hartwig, *Nature* **2015**, 517, 600–604; e) J. J. Topczewski, P. J. Cabrera, N. I. Saper, M. S. Sanford, *Nature* **2016**, 531, 220–224; f) L. McMurray, F. O'Hara, M. J. Gaunt, *Chem. Soc. Rev.* **2011**, 40, 1885–1898; g) A. McNally, B. Haffemayer, B. S. Collins, M. J. Gaunt, *Nature* **2014**, 510, 129–133; h) F.-L. Zhang, K. Hong, Tuan-Jie Li, H. Park, J.-Q. Yu, *Science* **2016**, 351, 252–256; i) F. O'Hara, D. G. Blackmond, P. S. Baran, *J. Am. Chem. Soc.* **2013**, 135, 12122–12134; j) O. Abdulla, A. D. Clayton, R. A. Faulkner, D. M. Gill, C. R. Rice, S. M. Walton, J. B. Sweeney, *Chem., Eur. J.* **2017**, 23, 1494–1497; k) A. F. Noisier, M. A. Brimble, *Chem. Rev.* **2014**, 114, 8775–8806; l) J. P. Barham, M. P. John, J. A. Murphy, *J. Am. Chem. Soc.* **2016**, 138, 15482–15487; m) J. He, L. G. Hamann, H. M. Davies, R. E. Beckwith, *Nat. Commun.* **2015**, 6, 5943; n) Q. Michaudel, G. Journot, A. Regueiro-Ren, A. Goswami, Z. Guo, T. P. Tully, L. Zou, R. O. Ramabhadran, K. N. Houk, P. S. Baran, *Angew. Chem. Int. Ed. Engl.* **2014**, 53, 12091–12096; o) D. A. Nagib, D. W. MacMillan, *Nature* **2011**, 480, 224–228; p) Y. Zhu, M. Bauer, L. Ackermann, *Chem. Eur. J.* **2015**, 21, 9980–9983; q) F. Yang, J. Koeller, L. Ackermann, *Angew. Chem. Int. Ed.* **2016**, 55, 4759–4762.
- [3] a) J. Spencer, B. Z. Chowdhry, A. I. Mallet, R. P. Rathnam, T. Adatia, A. Bashall, F. Rominger, *Tetrahedron* **2008**, 64, 6082–6089; b) R. Khan, R. Felix, P. D. Kemmitt, S. J. Coles, I. J. Day, G. J. Tizzard, J. Spencer, *Adv. Synth. Catal.* **2016**, 358, 98–109.
- [4] a) E. A. Merritt, B. Olofsson, *Angew. Chem. Int. Ed. Engl.* **2009**, 48, 9052–9070; b) M. S. Yusubov, A. V. Maskaeve, V. V. Zhdankin, *Arkivoc* **2011**, 1, 370–409; c) S. G. Modha, M. F. Greaney, *J. Am. Chem. Soc.* **2015**, 137, 1416–1419.
- [5] a) D. Kalyani, K. B. McMurtrey, S. R. Neufeldt, M. S. Sanford, *J. Am. Chem. Soc.* **2011**, 133, 18566–18569; b) J. Jiang, W. M. Zhang, J. J. Dai, J. Xu, H. J. Xu, *J. Org. Chem.* **2017**, 82, 3622–3630; c) M. Majek, A. Jacobi von Wangelin, *Acc. Chem. Res.* **2016**, 49, 2316–2327; d) L. Marzo, I. Ghosh, F. Esteban, B. König, *ACS Catal.* **2016**, 6, 6780–6784; e) D. P. Hari, P. Schroll, B. König, *J. Am. Chem. Soc.* **2012**, 134, 2958–2961.
- [6] S. J. Coles, P. A. Gale, *Chem. Sci.* **2012**, 3, 683–689.
- [7] a) J. F. Bunnett, R. E. Zahler, *Chem. Rev.* **1951**, 273–412; b) I. K. Barbem, H. Suschitz, *J. Chem. Soc.* **1960**, 2735–2739.
- [8] J. R. Attack, K. A. Wafford, S. J. Tye, S. M. Cook, B. Sohal, A. Pike, C. Sur, D. Melillo, L. Bristow, F. Bromidge, I. Ragan, J. Kerby, L. Street, R. Carling, J. L. Castro, P. Whiting, G. R. Dawson, R. M. McKernan, *J. Pharmacol. Exp. Ther.* **2006**, 316, 410–422.
- [9] D. L. Davies, S. M. A. Donald, S. A. Macgregor, *J. Am. Chem. Soc.* **2005**, 127, 13754–13755.
- [10] A. Vigalok, O. Uzan, L. J. W. Shimon, Y. Ben-David, J. M. L. Martin, D. Milstein, *J. Am. Chem. Soc.* **1998**, 120, 12539–12544.
- [11] F. Teplý, *Collection Czech Chem. Comm.* **2011**, 76, 859–917.

- [12] a) J. R. Khusnutdinova, N. P. Rath, L. M. Mirica, *J. Am. Chem. Soc.* **2010**, *132*, 7303–7305. b) D. C. Powers, T. Ritter, *Nat. Chem.* **2009**, *1*, 302–309.
- [13] a) R. A. Marcus, *Ann. Rev. Phys. Chem.* **1964**, *15*, 155–196; b) R. A. Marcus, *J. Chem. Phys.* **1956**, *24*, 966–978; c) R. A. Marcus, *J. Chem. Phys.* **1956**, *24*, 979–989; d) J.-M. Saveant, *J. Am. Chem. Soc.* **1987**, *109*, 6788–6795.
- [14] Q. Zhang, Z.-Q. Zhang, Y. Fu, H.-Z. Yu, *ACS Catal.* **2016**, *6*, 798–808.
- [15] A. Ariafard, C. J. T. Hyland, A. J. Canty, M. Sharma, B. F. Yates, *Inorg. Chem.* **2011**, *50*, 6449–6457.
- [16] A. J. Canty, A. Ariafard, M. S. Sanford, B. F. Yates, *Organometallics* **2013**, *32*, 544–555.
- [17] H. Ossor, M. Pfeffer, J. T. B. H. Jastrzebski, C. H. Stam, *Inorg. Chem.* **1987**, *26*, 1169–1117 1161.
- [18] a) P. Hanson, J. R. Jones, A. B. Taylor, P. H. Walton, A. W. Timms, *J. Chem. Soc. Perkin Trans. 2* **2002**, 1135–1150; b) B. Schmidt, R. Berger, F. Holter, *Org. Biomol. Chem.* **2010**, *8*, 1406–1414.
- [19] S. H. Korzeniowski, A. Leopold, J. R. Beadle, M. F. Ahern, W. A. Sheppard, R. K. Khanna, G. W. Gokel, *J. Org. Chem.* **1981**, *46*, 2153–2159.
- [20] M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, et al., Gaussian Inc., Wallingford, CT, **2009**.
- [21] D. Andrae, U. HuBermann, M. Dolg, H. Stoll, H. PreuB, *Theor. Chim. Acta* **1990**, *77*, 123–141.
- [22] J. P. Perdew, K. Burke, M. Ernzerhof, *Phys. Rev. Lett.* **1997**, *77*, 1396.
- [23] a) S. Boonseng, G. W. Roffe, J. Spencer, H. Cox, *Dalton Trans.* **2015**, *44*, 7570–7577; b) P. Surawatanawong, M. B. Hall, *Organometallics* **2008**, *27*, 6222–6232.
- [24] J. D. Chai, M. Head-Gordon, *Phys. Chem. Chem. Phys.* **2008**, *10*, 6615–6620.
- [25] a) Y. Minenkov, G. Occhipinti, V. R. Jensen, *J. Phys. Chem. A* **2009**, *113*, 11833–11844; b) N. Sieffert, M. Buhl, *Inorg. Chem.* **2009**, *48*, 4622–4624; c) M. L. Laury, A. K. Wilson, *J. Chem. Theory Comput.* **2013**, *9*, 3939–3946; d) Y. Zhao, D. G. Truhlar, *J. Chem. Theory Comput.* **2011**, *7*, 669–676.
- [26] a) V. Barone, M. Cossi, *J. Phys. Chem. A* **1998**, *102*, 1995–2001; b) M. Cossi, N. Rega, G. Scalmani, V. Barone, *J. Comp. Chem.* **2003**, *24*, 669–681.
- [27] a) G. O. Jones, P. Liu, K. N. Houk, S. L. Buchwald, *J. Am. Chem. Soc.* **2010**, *132*, 6205–6213; b) C. Y. Lin, M. L. Coote, A. Gennaro, K. Matyjaszewski, *J. Am. Chem. Soc.*, **2008**, *130*, 12762–12774.
- [28] R. A. Marcus, N. Sutin, *Biochimica et Biophysica Acta* **1985**, *811*, 265–322.